top of page
Search

ADC Series (X) ADC Market & Strategy：How Antibody–Drug Conjugates Are Reshaping Biotech Competition


Circular infographic of ADC Market, showing layers: Clinical, Biotech, Technology Modules, Business. Contains icons, arrows, and blue tones.




Executive Summary



Antibody–drug conjugates (ADCs) have rapidly evolved from an innovative therapeutic modality into one of the most strategically important areas in the biotech industry.


In recent years, the ADC market has undergone significant changes:


  • A surge in licensing deals and M&A activity

  • Increasing investment from large pharmaceutical companies in ADC pipelines

  • Growing focus among biotech startups on ADC platform technologies



These trends indicate that:


The ADC market has become one of the most active and competitive segments in oncology

This article explores:


  • Why the ADC market has become a major industry focus

  • Strategic differences between large pharma and biotech startups

  • Competitive dynamics of ADC pipelines

  • Market and deal trends from 2023 to 2026

  • Future directions of the ADC industry





1. Why Has the ADC Market Become a Hot Area?





1️⃣ Clinical Success Has Driven Market Confidence



Recent ADC success stories include:


  • Enhertu (trastuzumab deruxtecan)

  • Trodelvy



These demonstrate that ADCs offer:


  • strong anti-tumor efficacy

  • expandable indications



👉 These clinical successes have directly fueled investment and deal activity in the ADC market




2️⃣ Unmet Medical Need



Many cancers still:


  • lack effective therapies

  • develop resistance to existing treatments



👉 ADCs provide new therapeutic opportunities, expanding the overall market potential




3️⃣ Platform Expandability



ADCs can be optimized by modifying:


  • antibody

  • payload

  • linker



👉 enabling faster pipeline expansion



👉 Together, these factors create a powerful intersection of:


science × clinical success × capital, driving rapid growth of the ADC market




2. Big Pharma Strategy: The Core Driver of the ADC Market





Key Trend



Large pharmaceutical companies are not only developing ADCs internally, but increasingly acquiring innovation externally



Major Approaches




Licensing



  • upfront payments

  • milestone payments

  • royalties





M&A



  • acquiring biotech companies with ADC platforms or pipelines





Representative Examples



  • AstraZeneca × Daiichi Sankyo (Enhertu)

  • Pfizer acquisition of Seagen (2023)

  • AbbVie acquisition of ImmunoGen (2023)



👉 These examples highlight that the ADC market has become a central battlefield for business development (BD)




🔥 Emerging Trend (2025–2026)



ADC and broader biotech M&A are shifting structurally:


👉 Mid-sized acquisitions ($1B–$10B) are becoming dominant


These “bolt-on acquisitions”:


  • strengthen specific technologies or pipelines

  • reduce overall risk

  • improve integration efficiency



👉 This indicates that the ADC market is entering a phase of:


strategic allocation




Recent Examples (2026)



  • Biogen acquisition of Apellis (~$5.6B; not an ADC company, but reflects similar BD logic)

  • Continued acquisitions of innovative biotech companies by Lilly and Merck



👉 These moves suggest:


Large pharma is systematically externalizing innovation



3. ADC Company Types (Biotech Strategy Perspective)





1️⃣ Platform Companies



Focus on:


  • linker technologies

  • payload development

  • delivery systems



👉 With successful licensing or pipeline generation, these companies often have higher valuation potential




2️⃣ Asset Companies



Focus on:


  • one or a few ADC products



👉 Faster development timelines but higher concentration risk




3️⃣ Hybrid Model



Combine:


  • platform + pipeline



👉 Balance short-term value and long-term growth



👉 These strategies directly impact:


  • fundraising ability

  • BD opportunities

  • market positioning





4. Competitive Dynamics of ADC Pipelines





Multiple Players Target the Same Antigens



Examples:


  • HER2

  • Trop-2





Where Does Differentiation Come From?



👉 Not just the target, but:


  • payload design

  • linker technology

  • safety profile

  • clinical strategy




👉 The ADC market has entered a stage of:


fine differentiation competition




5. How Can Startups Enter the ADC Market?





Key Strategies



1️⃣ Focus on unmet needs

2️⃣ Build licensable platforms

3️⃣ Target niche indications



👉 The key to success:


strategic positioning



6. Key Risks in the ADC Market





Scientific Risks



  • target biology

  • resistance mechanisms





Clinical Risks



  • toxicity

  • trial failure





Manufacturing Risks



  • CMC complexity

  • scale-up challenges





Market Risks



  • overcrowded competition

  • insufficient differentiation




👉 The ADC market represents:


high reward × high risk




7. 2023–2026 ADC Deal Timeline (Key Industry Signals)





2023



  • Pfizer acquires Seagen

  • AbbVie acquires ImmunoGen



👉 The ADC market enters a consolidation phase




2024



  • Multiple ADC licensing deals exceeding $1B

  • Rapid pipeline expansion





2025



  • Continued strong dealmaking activity

  • Increasing focus on platform technologies





2026



  • Mid-sized M&A becomes dominant

  • Continued external innovation acquisition by pharma

  • The ADC market enters a mature competitive phase




👉 Key signal:


ADCs have transitioned from a “technology opportunity” to a “capital-driven competitive battlefield”



8. Future Directions of the ADC Market





Technology Trends



  • multispecific ADCs

  • dual-payload ADCs

  • next-generation linkers





Clinical Trends



  • combination therapies

  • biomarker-driven trials





Industry Trends



  • platformization

  • accelerated BD activity

  • ecosystem formation




👉 The ADC market is evolving into a:


multi-layered ecosystem spanning technology, clinical development, and business strategy




🔥 Key Insight



A clear industry signal is:


ADCs are no longer just a drug modality, but a central arena where capital and technology compete simultaneously

As the ADC market continues to evolve:


👉 long-term success will depend on overall strategy, not just individual technological advantages




From Technology to Strategy | LuTra Studio Consulting



Successful ADC development requires integration across:


  • science

  • clinical execution

  • manufacturing

  • business strategy



At LuTra Studio, we support teams by:


  • designing ADC strategies

  • evaluating pipelines

  • planning BD pathways

  • integrating technology with market positioning



so that companies do not just develop products, but:


👉 build sustainable competitive advantages

Comments

bottom of page